| Description |
1 online resource |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Note |
Online resource; title from PDF title page (EBSCO, viewed January 8, 2019). |
| Contents |
1. INTRODUCTION -- 2. INTRACELLULAR TRAFFICKING OF THE EGFR AND RESISTANCE TO ANTI-EGFR THERAPY -- 3. THE RAS/REF/MEK/ERK SIGNALING PATHWAY AND RESISTANCE TO ANTI-EGFR THERAPY -- 3.1. Growth Factor Receptor-bound Protein 2 (Grb2) -- 3.2. RAS -- 3.2.1. The Role of K-RAS in Primary Resistance -- 3.2.2. The Role of K-RAS in Acquired Resistance -- 3.3. RAF -- 3.4. MAPK Extracellular Signal-regulated Kinase (MEK) and Extracellular Signal-regulated Kinase (ERK1/2) -- 3.5. Dual-Specificity MAP Kinase Phosphatases (DUSPs) -- 4. THE PI3-K SIGNALING PATHWAY AND RESISTANCE TO ANTI-EGFR THERAPY -- 4.1. Phosphatidylinositol 3-kinase (PI3-K) -- 4.2. PTEN -- 5. ANALYSIS OF SEVERAL BIOMARKERS IN COMBINATION AND RESISTANCE TO ANTI-EGFR THERAPY -- 6. THE JAK/STAT SIGNALING PATHWAY AND RESISTANCE TO ANTI-EGFR THERAPY -- CONCLUDING REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Chemotherapeutic, Immunologic, and Molecularly Targeted Therapy for the Treatment of Advanced Melanoma -- INTRODUCTION -- CHEMOTHERAPEUTIC AGENTS -- Alkylating Agents -- Dacarbazine -- Temozolomide -- Platinum Compounds -- Taxanes -- Nitrosureas -- Chemotherapy in Combination -- IMMUNOTHERAPY -- Interferon Alpha -- Interleukin-2 (IL-2) -- Vaccine Therapy -- Peptide Vaccines -- Adoptive Cell Therapy -- Immune Checkpoint Inhibitors -- Immune Checkpoint Inhibitors in Combination -- MOLECULARLY TARGETED THERAPY -- MAPK Signaling Pathway -- BRAF Inhibitors -- MEK Inhibitors -- C-KIT Inhibitors -- Molecularly Targeted Therapies in Combination -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Targeting the Warburg Effect for Cancer Therapy: A Long and Winding Road -- 1. THERAPEUTICAL APPROACHES TO CANCER: FROM CHEMOTHERAPY TO TARGETED THERAPIES -- 2. BIOENERGETICS: A VERY BRIEF OVERVIEW -- 3. THE WARBURG EFFECT: CURRENT PERSPECTIVE. |
|
4. CURRENT AND PAST EFFORTS AT TARGETING THE WARBURG EFFECT FOR CANCER THERAPY -- CONCLUDING REMARKS -- NOTES -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Immunotherapy Strategies in Follicular Lymphoma: Antibodies, Vaccines and Cells -- 1. INTRODUCTION -- 2. BIOLOGY OF FOLLICULAR LYMPHOMA -- 2.1. Histopathology of FL -- 2.2. Follicular Lymphoma-cell Origin -- 2.3. Follicular Lymphoma Microenvironment -- 3. PREVIOUS CONSIDERATIONS BEFORE THERAPY -- 3.1. Who should be Treated, and When? -- 3.2. How to define Treatment Intensity -- 4. FIRST LINE TREATMENT -- 4.1. Early-stage Disease -- 4.2. Induction Treatment for Advanced Stages -- 4.3. Consolidation Treatment -- 4.3.1. Interferon Maintenance -- 4.3.2. Rituximab Maintenance -- 4.3.3. Autologous Stem-cell Transplantation -- 4.3.4. Radioimmunotherapy -- 5. RELAPSE TREATMENT -- 5.1. Choice of Rescue Treatment -- 5.2. Bortezomib for FL Relapse -- 5.3. Autologous Stem-cell Transplantation for FL Relapse -- 5.4. Radioimmunotherapy for FL Relapse -- 5.5. Rituximab Maintenance for FL Relapse -- 5.6. Role of Allogeneic SCT -- 6. NOVEL AND EMERGING PHARMACOLOGICAL AGENTS -- 7. INNOVATIVE IMMUNOTHERAPY STRATEGIES FOR TREATMENT OF FL -- 7.1. Passive Immunotherapy: Adoptive Cell Therapy -- 7.1.1. LAK Cells -- 7.1.2. NK Cells -- 7.1.3. Antigen-specific T Cells -- 7.1.4. Treatment Combinations: Rituximab and Effector Cells -- 7.2. Active Immunotherapy Strategies: Vaccines -- 7.2.1. Idiotype Protein Vaccines -- 7.2.2. DNA Vaccines -- 7.2.3. Dendritic Cell Vaccines -- 7.2.4. Membrane Proteoliposomal Vaccines -- 7.2.5. Strategies to Enhance Immunogenicity -- 7.3. New Targets for Immunotherapy -- 7.4. Future Directions in Vaccine Development -- CONCLUDING REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES. |
|
Epigenetics and Cancer Cell Metabolism: Cross-talk and Therapeutic Opportunities -- INTRODUCTION -- CANCER EPIGENETICS AND ROLE IN CARCINOGENESIS -- DNA Methylation -- Histone Modifications -- Non-coding RNA -- CANCER METABOLISM -- The Warburg's Hypothesis: Deregulated Metabolism in Cancer -- Pathways Leading to Altered Metabolism in Tumors -- Epigenetics and Metabolism: Crosstalk -- MODULATION OF METABOLISM BY EPIGENETIC DYS-REGULATION -- Modulation of Metabolism by DNA Methylation -- Modulation of Metabolism by Histone Modifications -- Modulation of Metabolism by miRNAs -- EPIGENETIC REGULATION BY THE AVAILABILITY OF CO-SUBSTRATES -- Acetyl-CoA and Histone Acetylation -- S-adenosylmethionine and DNA and Histone Methylation -- EPIGENETIC DYSREGULATION INDUCED BY ONCOMETABOLITES -- 2-Hydroxylglutarate Production in IDH1 and IDH2 Mutant Cancers -- 2-Hydroxylglutarate Modulates DNA Methylation -- 2-Hydroxylglutarate Modulates Histone Methylation -- Succinate and Fumarate Modulate DNA and Histone Methylation -- THERAPEUTIC OPPORTUNITIES -- DNMT Inhibitors -- HDAC Inhibitors (HDACi) -- miRNA Targeting Agents -- IDH1 and IDH2 Inhibitors -- CONCLUDING REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Apoptosis Targeting Therapeutics in Clinical Trials -- CANCER -- APOPTOSIS -- MECHANISMS OF APOPTOSIS -- TARGETING P53 -- p53-based Gene Therapy -- p53-based Immunotherapy -- p53-based Drug Therapy -- ANTI-APOPTOTIC PROTEINS -- Targeting the MDM2-p53 Complex -- Nutlins -- RG7112 -- MK-8242 and MI-888 -- MI-219 -- SAR405838 (MI-77301) -- CGM097 -- Other MDM2 Inhibitors -- Targeting the IAPs -- OGX-011 -- GDC-0152 and GDC-0917 (CUDC-427) (Genentech) -- AEG40826/HGS1029 (Aegera/Human Genome Sciences) -- LCL161 (Novartis) -- SM-406/AT-406/Debio 1143 (University of Michigan/Ascenta/DebioPharm) -- SM-164 -- LBW242 -- Other IAP Antagonists. |
|
Targeting the BCL Family of Proteins -- ABT-737 and ABT-263 (navitoclax) -- ABT-199 (GDC-0199/venetoclax, AbbVie) -- Obatoclax Mesylate (GX15-070) (Gemin X/Teva) -- AT-101 R-(−)-gossypol (Ascenta) -- OTHER APOPTOSIS INDUCERS [44] -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- SUBJECT INDEX. |
| Summary |
Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The fourth volume of the book brings forth reviews on biomarkers and new drugs used for treating gastrointestinal cancer and breast cancer. The volume also covers the topics of adjuvant therapy, cancer nanodrugs and the role of adiponectin and dicycloplatin in cancer therapy. |
| Subject |
Cancer -- Alternative treatment.
|
|
Antineoplastic agents.
|
|
Cancer -- Médecines parallèles.
|
|
Anticancéreux.
|
|
HEALTH & FITNESS / Diseases / General.
|
|
MEDICAL / Clinical Medicine.
|
|
MEDICAL / Diseases.
|
|
MEDICAL / Evidence-Based Medicine.
|
|
MEDICAL / Internal Medicine.
|
|
Antineoplastic agents
|
|
Cancer -- Alternative treatment
|
| ISBN |
1681082896 (electronic bk.) |
|
9781681082899 (electronic bk.) |
|
